The US House of Representatives agreed Jan.18 to delay implementation of the medical device excise tax for another two years, until January 2020. The delay is part of a continuing resolution to fund the government until Feb. 16, and support the Children's Health Insurance Program for six more years. Industry groups are jubilant at the tax reprieve, but the budget plan also needs Senate approval.
Less than two weeks before the first new payments are technically due, the US House has approved a provision to delay the 2.3% device excise tax for another two years. The measure was included in a continuing resolution bill to keep the federal government funded until Feb. 16, so congressional budget negotiators have more time to complete a full 2018 spending plan.
But while the device tax-delay provision – as well as a six-year funding agreement for Children's Health Insurance Program –...
Children with biliary atresia (BA) exhibited neurodevelopmental deficits and increased autism traits, with earlier surgery linked to better general neurodevelopment.
Multi-cancer diagnostics can help get oncology patients the treatment they need more quickly, but lack of reimbursement has kept such tests out of reach for many patients. Bills providing coverage have passed or are under consideration in more than half of the states and have been introduced in both houses of US Congress.
A government report requested by US lawmakers Debbie Dingell and Anna Eshoo to review the FDA’s postmarket surveillance of medical devices stresses that strengthening the system is critical to addressing adverse events linked to devices after they hit the market.
A bipartisan bill now in the US Senate seeks to change the classification of implantable hearing aid devices to allow Medicare to reimburse for the devices, potentially expanding access for many Americans who require them.
This week, Establishment Labs Holdings announced the FDA gave it premarket approval for Motiva breast implant, Cologuard lands FDA approval for Cologuard Plus and GE HealthCare gets FDA nod for a new imaging agent. The FDA announces another expansion for TAP into ophthalmology and radiology. The AAMI and CTA will join forces to develop standards for AI and ML-enabled health care products.
Children with biliary atresia (BA) exhibited neurodevelopmental deficits and increased autism traits, with earlier surgery linked to better general neurodevelopment.
